Bibliography
- Lotvall J. Pharmacological similarities and differences between beta2-agonists. Respir Med 2001;95(Suppl B):S7-11
- Johnson M. Salmeterol. Med Res Rev 1995;15:225-57
- Green SA, Spasoff AP, Coleman RA, et al. Sustained activation of a G protein-coupled receptor via “anchored” agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 1996;271:24029-35
- Currie GP. Indacaterol Novartis/SkyePharma. Curr Opin Investig Drugs 2006;7:457-63
- Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol 1998;53:128-34
- Astrazeneca AB. 7-(2-Amino-1-hydroxyethyl)-4-Hydroxybenzothiazol-2(3H)-One-Derivatives As β2 Adrenoceptor Agonists. WO2007027134; 2007
- Astrazeneca AB. Novel Benzothiazolone Derivatives. WO2007018461; 2007
- Calverley P, Keating ET, Goldman M, Casty F. Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications. Respir Med 2003;97(Suppl A):S71-4
- Norman P. AstraZeneca's long acting M3 antagonists. Exp Opin Ther Pat 2009
- Norman P. AZD-4818, a CCR1 antagonist. Exp Opin Ther Pat 2009